VANTRELA ER Drug Patent Profile

✉ Email this page to a colleague

When do Vantrela Er patents expire, and what generic alternatives are available?

Vantrela Er is a drug marketed by Teva Branded Pharm and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-three patent family members in thirteen countries.

The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vantrela Er

A generic version of VANTRELA ER was approved as hydrocodone bitartrate by ALVOGEN on January 21^st, 2020.

Sign Up

Summary for VANTRELA ER

International Patents:	33
US Patents:	3
Applicants:	1
NDAs:	1
Formulation / Manufacturing:	see details
DailyMed Link:	VANTRELA ER at DailyMed

Drug patent expirations by year for VANTRELA ER

Anatomical Therapeutic Chemical (ATC) Classes for VANTRELA ER

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

US Patents and Regulatory Information for VANTRELA ER

VANTRELA ER is protected by three US patents.

Patents protecting VANTRELA ER

Abuse resistant drug formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-001	Jan 17, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-003	Jan 17, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-002	Jan 17, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-004	Jan 17, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-003	Jan 17, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-005	Jan 17, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-001	Jan 17, 2017		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for VANTRELA ER

When does loss-of-exclusivity occur for VANTRELA ER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Patent: 63172
Estimated Expiration: ⤷ Sign Up

Patent: 99142
Estimated Expiration: ⤷ Sign Up

Cyprus

Patent: 15005
Estimated Expiration: ⤷ Sign Up

Patent: 16598
Estimated Expiration: ⤷ Sign Up

Denmark

Patent: 73795
Estimated Expiration: ⤷ Sign Up

Patent: 00593
Estimated Expiration: ⤷ Sign Up

Patent: 92341
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 73795
Estimated Expiration: ⤷ Sign Up

Patent: 00593
Estimated Expiration: ⤷ Sign Up

Patent: 92341
Estimated Expiration: ⤷ Sign Up

Hong Kong

Patent: 34775
Estimated Expiration: ⤷ Sign Up

Patent: 93567
Estimated Expiration: ⤷ Sign Up

Hungary

Patent: 27128
Estimated Expiration: ⤷ Sign Up

Patent: 32012
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 57032
Estimated Expiration: ⤷ Sign Up

Patent: 30572
Estimated Expiration: ⤷ Sign Up

Patent: 11504455
Estimated Expiration: ⤷ Sign Up

Patent: 11517654
Estimated Expiration: ⤷ Sign Up

Mexico

Patent: 6861
Estimated Expiration: ⤷ Sign Up

Patent: 09002757
Estimated Expiration: ⤷ Sign Up

Patent: 10002780
Estimated Expiration: ⤷ Sign Up

Poland

Patent: 73795
Estimated Expiration: ⤷ Sign Up

Patent: 00593
Estimated Expiration: ⤷ Sign Up

Patent: 92341
Estimated Expiration: ⤷ Sign Up

Portugal

Patent: 73795
Estimated Expiration: ⤷ Sign Up

Patent: 92341
Estimated Expiration: ⤷ Sign Up

Slovenia

Patent: 73795
Estimated Expiration: ⤷ Sign Up

Patent: 92341
Estimated Expiration: ⤷ Sign Up

Spain

Patent: 52033
Estimated Expiration: ⤷ Sign Up

Patent: 43802
Estimated Expiration: ⤷ Sign Up

Patent: 11794
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VANTRELA ER around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Mexico	336861	FORMULACION DE FARMACO RESISTENTE AL ABUSO. (ABUSE RESISTANT DRUG FORMULATION.)	⤷ Sign Up
Portugal	2692341		⤷ Sign Up
European Patent Office	2073795	PRÉPARATION MÉDICAMENTEUSE EMPÊCHANT L'UTILISATION ABUSIVE (ABUSE RESISTANT DRUG FORMULATION)	⤷ Sign Up
Hong Kong	1134775	抗濫用藥物製劑 (ABUSE RESISTANT DRUG FORMULATION)	⤷ Sign Up
Spain	2452033		⤷ Sign Up
Poland	2692341		⤷ Sign Up
Spain	2611794		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for VANTRELA ER

Anatomical Therapeutic Chemical (ATC) Classes for VANTRELA ER

Patents protecting VANTRELA ER

When does loss-of-exclusivity occur for VANTRELA ER?

Make Better Decisions: Try a trial or see plans & pricing